Thiadiazole derivatives as antidiabetic agents

Details for Australian Patent Application No. 2006321905 (hide)

Owner Novartis AG

Inventors Nakajima, Katsumasa; Topiol, Sidney Wolf; Wareing, James Richard; Barnes, David; Bebernitz, Gregory Raymond; Vedananda, Thalaththani Ralalage; Stams, Travis; Coppola, Gary Mark

Agent Davies Collison Cave

Pub. Number AU-B-2006321905

PCT Pub. Number WO2007/067615

Priority 60/748,573 08.12.05 US

Filing date 6 December 2006

Wipo publication date 14 June 2007

Acceptance publication date 11 August 2011

International Classifications

C07D 285/10 (2006.01) Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups

A61K 31/433 (2006.01) - Thiadiazoles

A61P 3/10 (2006.01) Drugs for disorders of the metabolism

C07D 417/04 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group

C07D 417/10 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group

Event Publications

26 June 2008 PCT application entered the National Phase

  PCT publication WO2007/067615 Priority application(s): WO2007/067615

11 August 2011 Application Accepted

  Published as AU-B-2006321905

8 December 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006321906-Uses of myostatin antagonists

2006321904-I, l , 3-trioxo-l , 2 , 5-thiadiazolidines and their use as PTP-ases inhibitors